620 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Foguth Wealth Management LLC.

Foguth Wealth Management LLC. purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 620 shares of the company’s stock, valued at approximately $482,000.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Gotham Asset Management LLC raised its position in Eli Lilly and Company by 111.3% during the 3rd quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock valued at $3,967,000 after purchasing an additional 3,891 shares in the last quarter. Logan Capital Management Inc. increased its holdings in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Logan Capital Management Inc. now owns 35,290 shares of the company’s stock valued at $18,955,000 after acquiring an additional 302 shares during the period. Hodges Capital Management Inc. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $4,078,000. Insigneo Advisory Services LLC increased its holdings in shares of Eli Lilly and Company by 16.4% in the 3rd quarter. Insigneo Advisory Services LLC now owns 3,125 shares of the company’s stock valued at $1,679,000 after acquiring an additional 440 shares during the period. Finally, AQR Capital Management LLC increased its holdings in shares of Eli Lilly and Company by 0.5% in the 3rd quarter. AQR Capital Management LLC now owns 305,633 shares of the company’s stock valued at $164,165,000 after acquiring an additional 1,448 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE LLY traded down $3.66 during trading hours on Friday, reaching $905.38. The company’s stock had a trading volume of 3,375,426 shares, compared to its average volume of 2,579,751. The firm has a market capitalization of $860.48 billion, a price-to-earnings ratio of 133.34, a P/E/G ratio of 1.98 and a beta of 0.36. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $915.54. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company’s 50-day moving average is $814.40 and its two-hundred day moving average is $739.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.62 EPS. On average, equities analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Argus boosted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, June 24th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $812.72.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 17,229 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the completion of the sale, the insider now directly owns 97,556,910 shares in the company, valued at approximately $88,033,404,445.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 17,229 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the completion of the sale, the insider now directly owns 97,556,910 shares in the company, valued at approximately $88,033,404,445.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 789,704 shares of company stock valued at $672,385,964. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.